CXCL13 Is A Biomarker Of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients
You-ting Lin,1 Xue Yang,2 Jing-wei Lv,2 Xue-wu Liu,2,* Sheng-jun Wang2,* 1Department of Neurology, Shandong Provincial Hospital, Shandong University, Ji’nan, People’s Republic of China; 2Department of Neurology, Qilu Hospital, Shandong University, Ji’nan, People&rsq...
Guardado en:
Autores principales: | Lin Y, Yang X, Lv J, Liu X, Wang S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bcad2b20d19e46ea957cd8118e8661f9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
CXCL13 Is a Biomarker of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients [Letter]
por: Wei M, et al.
Publicado: (2020) -
Electrophysiological Evaluation in Identifying Unique Sleep Features Among Anti-LGI1 Encephalitis Patients During Active and Recovery Phase
por: Liu X, et al.
Publicado: (2021) -
THE CYTOKINES SYNTHESIS IN VITRO IN THE TICK-BORNE ENCEPHALITIS VIRUS INFECTED CELLS AND IN THE PRESENCE OF INACTIVATED VACCINE
por: M. V. Mesentseva, et al.
Publicado: (2014) -
CXCL13 Is a Biomarker of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients [Response to Letter]
por: Wang S, et al.
Publicado: (2020) -
Clinical Features and Long-Term Outcomes of Anti-Leucine-Rich Glioma-Inactivated 1 Encephalitis: A Multi-Center Study
por: Qiao S, et al.
Publicado: (2021)